| |
|
|
| |
|
 |
|
|
|
This activity has been designed to meet the educational
needs of hematologists and oncologists involved in the
management of sleep, insomnia, and cancer |
|
|
|
To provide important clinical data on the management of
sleep, insomnia, and cancer |
|
|
|
Upon completion of this activity, participants should be
better able to: |
|
|
|
• |
Review the characteristics and epidemiology of insomnia in
the general population |
|
• |
Describe the epidemiology, etiology, symptoms and
consequences of insomnia comorbid with cancer |
|
• |
Identify cancer stage – and treatment-related insomnia in
the patient with comorbid cancer |
|
• |
Review treatment options for insomnia in the patient with
comorbid cancer |
|
|
|
|
This activity has been planned and implemented in accordance
with the Essential Areas and Policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the
sponsorship of Purdue University School of Pharmacy an equal
opportunity, equal access institution and the Sleep Medicine
Education Institute. Purdue University School of Pharmacy is
accredited by the ACCME to provide continuing medical
education for physicians. |
|
|
|
Purdue University School of Pharmacy designates this
educational activity for a maximum of 1.0 AMA PRA Category 1
Credit(s)™. Physicians should only claim credit commensurate
with the extent of their participation in the activity. |
|
|
|
All faculty participating in continuing education activities
sponsored by Purdue University School of Pharmacy are
expected to disclose to the audience any real or apparent
commercial financial affiliations related to the content of
their presentations/materials. |
|
|
 |
| |
|
 |
Major funding for this program is
provided by
an educational grant from Sepracor and
additional support from Sanofi-Aventis |
 |
|
|
|
|
|
